Clinical trials increasingly recruit through digital channels such as social media advertisements and patient portal messages. However, to our knowledge, influencer marketing has not been described as ...
"We plan to initiate Phase III by September 2026" for OCU410 in geographic atrophy, and "we expect the OCU410ST interim outcome decision in the third quarter" of 2026. (CEO Musunuri) "We expect top ...
Welcome, everyone, to the Second Quarter of 2026 REGENXBIO Earnings Conference Call. My name is Elaine, and I will be your conference operator today. [Operator Instructions] At this time, I'd like to ...
Alzheimer’s disease (AD) is the most prevalent type of neuro-degenerative dementia. Artificial intelligence assisted clinical evaluation can improve diagnostic efficiency and facilitate timely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results